A Case of Herpes Zoster Ophthalmicus in a Recently Transplanted Renal Patient.

herpes zoster ophthalmicus shingle skin rash shingles complications trigeminal nerve varicella-zoster virus

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2023
Historique:
accepted: 24 06 2023
medline: 26 7 2023
pubmed: 26 7 2023
entrez: 26 7 2023
Statut: epublish

Résumé

Herpes Zoster Ophthalmicus (HZO) is a common manifestation of the reactivated Varicella Zoster virus, primarily affecting the eye and trigeminal nerve. This case study presents the clinical course of a 51-year-old male who underwent a renal transplant due to end-stage renal disease, further complicating the management of HZO. The patient's medical history also includes hypertension, type 2 diabetes mellitus, chronic kidney disease (CKD), cerebrovascular accident (CVA), and retinal detachment. Upon examination, the diagnosis of HZO was confirmed based on the presence of a characteristic unilateral vesicular rash in the V1 cranial nerve dermatomal distribution, accompanied by ophthalmic symptoms such as eyelid swelling and visual impairment. Given the patient's immunosuppressive regimen post-transplant, intravenous acyclovir was initiated for antiviral therapy, while supportive care was provided for pain control. Notably, the patient experienced a subsequent decrease in pain intensity and improvement in the vesicular rash. This case highlights the challenges in managing HZO in patients with a history of renal transplant and multiple comorbidities, emphasizing the importance of tailored treatment strategies to optimize patient outcomes. Further research is warranted to better understand the impact of immunosuppression and comorbidities on the course and management of HZO in this population.

Identifiants

pubmed: 37492822
doi: 10.7759/cureus.40899
pmc: PMC10365146
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e40899

Informations de copyright

Copyright © 2023, Jabin et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Trans Ophthalmol Soc U K (1962). 1983;103 ( Pt 1):111-4
pubmed: 6362108
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Neurology. 2013 Sep 3;81(10):928-30
pubmed: 23999562
N Engl J Med. 2002 Aug 1;347(5):340-6
pubmed: 12151472
Ophthalmology. 2008 Feb;115(2 Suppl):S3-12
pubmed: 18243930
Expert Rev Vaccines. 2017 Dec;16(12):1191-1201
pubmed: 29047317
Prim Care. 2015 Sep;42(3):285-303
pubmed: 26319339
Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):187-91
pubmed: 12644941
Cranio. 2001 Jan;19(1):8-12
pubmed: 11842844
Medicine (Baltimore). 1982 Sep;61(5):310-6
pubmed: 6981045
Am J Med. 1988 Aug 29;85(2A):84-9
pubmed: 3044099
S Afr Med J. 2010 Mar 08;100(3):172-4
pubmed: 20459942
J Virol. 2019 May 15;93(11):
pubmed: 30894469
Cornea. 2017 Mar;36(3):338-342
pubmed: 27741018
J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S2-6
pubmed: 19553632

Auteurs

Mohamad Jabin (M)

Medicine, Texas A&M College of Medicine, Bryan, USA.

Zaryab Alam (Z)

Medicine, Texas A&M College of Medicine, Bryan, USA.

Evan Chung (E)

Medicine, Burnett School of Medicine, Fort Worth, USA.

Mojahed Shalabi (M)

Internal Medicine, Baylor Scott & White All Saints, Fort Worth, USA.

Bismah Siddiqui (B)

Internal Medicine, Baylor Scott & White All Saints, Fort Worth, USA.

Classifications MeSH